3 minute read
Feb. 9, 2022
PF-07321332: an Oral, Reversible Covalent SARS-CoV-2 Main Protease Inhibitor
Pfizer CoV-2 MPro Inhibitor
oral pan-coronavirus antiviral, rev. covalent Ph. III candidate for COVID-19 (300 mg BID) from SARS-CoV-1 inhibitor (WO2005113580) paxlovid (PF-07321332) Pfizer Worldwide Research
Loading...
